Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.

ABSTRACT:

Background

Immune checkpoint inhibitors have transformed the management of triple-negative breast cancer (TNBC) but outcomes could be improved further. We explored combining the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) inhibitor tiragolumab with atezolizumab-containing regimens for patients with early-stage or advanced TNBC.

Patients and methods

This multinational open-label phase Ib study included two cohorts. In cohort A [programmed death-ligand 1 (PD-L1)-positive advanced TNBC], patients received first-line tiragolumab with atezolizumab and nab-paclitaxel. The primary endpoint was confirmed objective response rate. In cohort B (early-stage TNBC, irrespective of PD-L1 status), patients were randomised to receive tiragolumab, atezolizumab and seque

SUBMITTER: Kuemmel S 

PROVIDER: S-EPMC12689193 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature